Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials

European Journal of Cancer

Volumn 50, Issue 2, 2014, Pages 351-358

  Molina, A M ^a   Lin, X ^b   Korytowsky, B ^b   Matczak, E ^b   Lechuga, M J ^b   Wiltshire, R ^c   Motzer, R J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b PFIZER INC   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Metastatic renal cell carcinoma; Objective response; Sunitinib

Indexed keywords

SUNITINIB;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PATIENT HISTORY OF NEPHRECTOMY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; VERY ELDERLY;

EID: 84891831968     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.08.021     Document Type: Article

References (18)

1. R.G. Figueiras, A.R. Padhani, and V.J. Goh et al. Novel oncologic drugs: what they do and how they affect images Radiographics 31 2011 2059 2091
2. A.A.M. van der Veldt, M.R. Meijerink, A.J.M. van den Eertwegh, and E. Boven Targeted therapies in renal cell cancer: recent developments in imaging Target Oncol 5 2010 95 112
3. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
4. L.Q. Chow, and S.G. Eckhardt Sunitinib: from rational design to clinical efficacy J Clin Oncol 25 2007 884 896
5. R.J. Motzer, M.D. Michaelson, and B.G. Redman et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 16 24
6. R.J. Motzer, B.I. Rini, and R.M. Bukowski et al. Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2006 2516 2524
7. B. Escudier, J. Roigas, and S. Gillessen et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4068 4075
8. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
9. C.H. Barrios, D. Hernandez-Barajas, and M.P. Brown et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma Cancer 118 2012 1252 1259
10. R.J. Motzer, T.E. Hutson, and M.R. Olsen et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma J Clin Oncol 30 2012 1371 1377
11. E.J. Abel, S.H. Culp, N.M. Tannir, P. Tamboli, S.F. Matin, and C.G. Wood Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib Eur Urol 60 2011 1273 1279
12. A.A. van der Veldt, M.R. Meijerink, A.J. van den Eertwegh, J.B. Haanen, and E. Boven Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib Br J Cancer 102 2010 803 809
13. R.J. Motzer, J. Bacik, B.A. Murphy, P. Russo, and M. Mazumdar Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296
14. D.Y. Heng, W. Xie, and M.M. Regan et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
15. S. Patil, R.A. Figlin, and T.E. Hutson et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma Ann Oncol 22 2011 295 300
16. B.E. Houk, C.L. Bello, B. Poland, L.S. Rosen, G.D. Demetri, and R.J. Motzer Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis Cancer Chemother Pharmacol 66 2010 357 371
17. R. Khosravan, X. Huang, R. Wiltshire, M.J. Lechuga, and R.J. Motzer A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma: pitfalls of efficacy subgroup analyses based on dose-reduction status J Clin Oncol 30 Suppl. 5 2012 (Abstr. 363)
18. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response J Clin Oncol 1 1983 710 719